Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report)‘s stock had its “overweight” rating reaffirmed by Cantor Fitzgerald in a research report issued to clients and investors on Wednesday, Benzinga reports. They presently have a $65.00 price objective on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price target indicates a potential upside of 52.19% from the company’s current […]